TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

New stroke prevention device for TAVR holds its own in head-to-head battle with Sentinel
A new embolic protection device from Emboline was noninferior to the FDA-approved Sentinel device in terms of safety and efficacy. In addition, it captured much more TAVR-generated debris and was linked to an improved technical success rate.
When heart patients can’t wait: Urgent TAVR with self-expanding vs. balloon-expandable valves
The high-risk patients who require urgent or emergent TAVR are often excluded from major clinical trials. To learn more about this population, researchers explored data from nearly 600 patients treated at high-volume facilities.
Cleveland Clinic launches partnership focused on AI-powered TAVR planning
Cleveland Clinic, one of the world’s top heart hospitals, has launched a new two-part partnership with Ohio-based DASI Simulations.
Acute kidney injury after TAVR: Key risk factors every cardiologist should know
Multiple studies have linked acute kidney injury after TAVR to a heightened risk of short- and long-term mortality.
FDA approves JenaValve TAVR system for aortic regurgitation
The Trilogy Transcatheter Heart Valve System is the first TAVR device approved by the FDA to treat severe aortic regurgitation. Until now, interventional cardiologists have had to settle for the off-label use of TAVR valves built for treating aortic stenosis.

Adam Greenbaum, MD, presents late-breaking data at ACC.26.

New stroke prevention device for TAVR holds its own in head-to-head battle with Sentinel

A new embolic protection device from Emboline was noninferior to the FDA-approved Sentinel device in terms of safety and efficacy. In addition, it captured much more TAVR-generated debris and was linked to an improved technical success rate.

When heart patients can’t wait: Urgent TAVR with self-expanding vs. balloon-expandable valves

The high-risk patients who require urgent or emergent TAVR are often excluded from major clinical trials. To learn more about this population, researchers explored data from nearly 600 patients treated at high-volume facilities.

Cleveland Clinic launches partnership focused on AI-powered TAVR planning

Cleveland Clinic, one of the world’s top heart hospitals, has launched a new two-part partnership with Ohio-based DASI Simulations.

Acute kidney injury after TAVR: Key risk factors every cardiologist should know

Multiple studies have linked acute kidney injury after TAVR to a heightened risk of short- and long-term mortality.

FDA approves JenaValve TAVR system for aortic regurgitation

The Trilogy Transcatheter Heart Valve System is the first TAVR device approved by the FDA to treat severe aortic regurgitation. Until now, interventional cardiologists have had to settle for the off-label use of TAVR valves built for treating aortic stenosis.

Newsweek ranked the 50 best heart hospitals in the world

Moderate valve oversizing during TAVR boosts survival—too much may be less beneficial

Oversizing transcatheter heart valves can improve TAVR outcomes. There is still a reason to be cautious, however, especially when patients are receiving a balloon-expandable valve.

Cardiologists develop new AI screening tool for structural heart disease

Researchers have developed an advanced AI model capable of detecting signs of severe AS, mitral regurgitation and other complications in ECG results. For example, one 84-year-old patient who was hospitalized for a fractured femur ended up being scanned and treated with TAVR just days later.

World’s first polymeric TAVR valve impresses cardiologists—could improve durability, reduce costs

The new-look TAVR system was linked to multiple benefits after one year. The cardiologists evaluating this device belief it could significantly reduce the risk of long-term valve degeneration.